Search

[ES] En el presente artículo se describe el interfaz de la herramienta que se está desarrollando. La herramienta está dirigida al colectivo de profesionales de Oncología Pediátrica y Medicina Nuclear. El objetivo es mejorar la calidad de la interpretación de las exploraciones de gammagrafía con 123-I-mIBG, que se realizan a los pacientes con neuroblastoma. La recopilación y el análisis de la información tiene un gran potencial, ya que hasta la actualidad se viene realizando mediante inspección visual., [EN] In this article we describe the interface of the tool that is being developed. The tool is aimed at the group of Pediatric Oncology and Nuclear Medicine professionals. The objective is to improve the quality of the interpretation of 123-I-mIBG scintigraphy scans, which are performed on patients with neuroblastoma. The collection and analysis of information has great potential, since until now it has been carried out through visual inspection., Este proyecto se ha realizado con la ayuda de la Generalitat Valenciana, referencia AICO/2017/044 para el proyecto “HERRAMIENTA DE DIAGNÓSTICO PARA LA MEDICIÓN SEMICUANTITATIVA Y OBJETIVA DE IMÁGENES DE GAMMAGRAFÍA DE 123·1· MIBG DESTINADA A ONCOLOGIA PEDIÁTRICA”.

Whole-body 123I-Metaiodobenzylguanidine (mIBG) scintigraphy is used as primary image modality to visualize neuroblastoma tumours and metastases because it is the most sensitive and specific radioactive tracer in staging the disease and evaluating the response to treatment. However, especially in paediatric neuroblastoma, information from mIBG scans is difficult to extract because of acquisition difficulties that produce low definition images, with poor contours, resolution and contrast. These problems limit physician assessment. Current oncological guidelines are based on qualitative observer-dependant analysis. This makes comparing results taken at different moments of therapy, or in different institutions, difficult. In this paper, we present a computerized method that processes an image and calculates a quantitative measurement considered as its entropy, suitable for the identification of abnormal uptake regions, for which there is enough suspicion that they may be a tumour or metastatic site. This measurement can also be compared with future scintigraphies of the same patient. Over 46 scintigraphies of 22 anonymous patients were tested; the procedure identified 96.7% of regions of abnormal uptake and it showed a low overall false negative rate of 3.3%. This method provides assistance to physicians in diagnosing tumours and also allows the monitoring of patients’ evolution.

Nonlinear dynamics of cancer recurrence are known to be governed by several factors as initial tumour size, number of metastatic sites, or quantity of drug resistant cells. The precise extent and location of tumours are very important factors so quantitative and consistent methods of evaluation are needed to assess reponse to patient therapy. Whole-bodyI123-metaiodobenzylguanidine (mIBG) scintigraphy is used as primary medical image modality to detect neuroblastoma tumours due to its high specificity and sensitivity. However, current oncological guidelines are based on qualitative observer-dependent analysis. This fact makes it difficult to compare results of scintigraphies taken at different moments during therapy or at different institutions. In this paper, we review analytical methods used in neuroblastoma detection and propose an observer-independent method to quantitatively analyse aI123-mIBG scintigraphy.

Whole-body 123I-Metaiodobenzylguanidine (mIBG) scintigraphy is used as the primary image modality in neuroblastoma detection. It is the most sensitive and specific method for staging and response evaluation. Validated semi-quantitative scoring methods with low interobserver variability and high reproducibility have shown to be indispensable for the evaluation of response to therapy. However, low resolution, noise and acquisition difficulties, specially in children, make low definition scans. These facts increase observer dependent interpretations that limit assessment and complicate to put a scoring method succesfully into practice. It is essential to have an objective and reliable measure of response to test the activity of therapies. In this paper we propose the use of a quantitative observer-independent measurement of the strength of uptake to be used as an additional tool for assisting the International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN) semi-quantitative scoring method. This is the scoring method recommended by the SIOPEN Nuclear Medicine and Physics Committee, in collaborative work with the Children’s Oncology Group, as the standard one for acquiring and reporting diagnostic paediatric mIBG scans across Europe. Our proposed method is based on the ratio between the amount of specific uptake at tumours and the amount of non-specific uptake at SIOPEN anatomical sectors which has shown to be constant in all the scans of the patients., This work has been supported by "Ayudas para Actividades Preparatorias de Proyectos Coordinados entre Investigadores de la Universitat Politecnica de Valencia e Investigadores del Hospital Universitario y Politecnico La Fe", II Call, 2013, AUTOSCOREMIBG project. The authors are very grateful to the referees for their useful comments.